Pathkey.AI (ASX:PKY): AI Semiconductor and Healthcare Technology Ambitions Remain in Focus - Kalkine
Pathkey.AI (ASX:PKY): AI Semiconductor and Healthcare Technology Ambitions Remain in Focus Kalkine
Latest articles and price-sensitive announcements with AI sentiment classification.
Pathkey.AI (ASX:PKY): AI Semiconductor and Healthcare Technology Ambitions Remain in Focus Kalkine
Pathkey.AI (ASX:PKY) books first Chipforge contract before the platform even launches Stocks Down Under
Highlights PathKey.AI is developing separate artificial intelligence platforms for semiconductor design and clinical trial planning. Chipforge aims to reduce errors and delays across complex chip-development workflows. TrialKey uses clinical-trial data to identify protocol weaknesses before patient recruitment begins. PathKey.AI (ASX:PKY) is attracting attention with an unusual dual-platform strategy spanning semiconductor engineering and biotechnology. Its Chipforge platform is designed to au...
Pathkey.AI (ASX:PKY): An Exciting Dual‑Engine ASX AI Company With A Big 18 Months Ahead! Stocks Down Under
Parkway Corporate (ASX:PKY) Advances 5.26% as Water Treatment Projects Continue to Progress Kalkine
Pathkey.Ai (ASX:PKY) Eases Over 9% — What Is Pulling the AI Cybersecurity Stock Lower? Kalkine
LTDPATHKEY.AI (ASX: PKY) has revealed plans to issue 2,000,000 ordinary shares along with 30,000,000 options as part of a corporate advisory agreement. This issuance depends on successfully recruiting an appropriate adviser, director, or manager. This move highlights the company's strategic initiative to strengthen its advisory team and enhance investor confidence. Key Points Company: LTDPATHKEY.AI, ASX ticker: PKY Planned issuance of 2,000,000 ordinary shares and 30,000,000 options Scheduled...
other announcement
other announcement